1. Pink Sheet
  2. >>Vaccines

US FDA Bypasses Adcomm In Authorizing Second COVID Booster Because Decision ‘Straight-Forward’

 
• By Derrick Gingery

Advisory committee member says FDA's decision to authorize extra shots of Pfizer and Moderna vaccines for those 50 and older was a short-term solution and that VRBPAC should prioritize long-term issues related to the coronavirus.

Vaccine booster
A newly authorized vial for Moderna vaccine boosters also could help federal tracking systems. • Source: Alamy

The US Food and Drug Administration’s latest expansion of the COVID-19 vaccine emergency use authorization is the largest yet without consulting its advisory committee, but fits a recent pattern with incremental decisions.

The agency announced 29 March that it had authorized a second booster of the Pfizer Inc./BioNTech SE or Moderna, Inc. COVID-19 vaccine for those age 50 and older

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By Sue Sutter

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 
• By Derrick Gingery

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.